Home / HealthNews / Roche’s Hemlibra gets speedy FDA review for wider use

Roche’s Hemlibra gets speedy FDA review for wider use

ZURICH (Reuters) – Roche’s hemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company’s plans to muscle in on turf dominated by rivals including Shire.

FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann

The U.S. Food and Drug Administration granted breakthrough therapy designation to the medicine to be used in people who have not yet developed resistance to conventional treatments, called inhibitors, Roche said on Tuesday. Hemlibra is already approved for people with inhibitors, though Shire is fighting Roche in court seeking to halt expanded use of the medicine.

Reporting by John Miller, editing by John Revill

About admin

Check Also

Hungarian laboratory worker isolated after exposure to Ebola virus

BUDAPEST (Reuters) – A Hungarian laboratory worker has been isolated at a Budapest hospital after …

Leave a Reply

Your email address will not be published. Required fields are marked *